内容紹介
Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin―A Case Report
Summary
Chemotherapy with S-1 and oxaliplatin is a new treatment for metastatic colorectal cancer. We present the first case of S-1, oxaliplatin, and bevacizumab therapy in our hospital. The patient was a 69-year-old woman with ascending colon cancer and multiple lung and liver metastases. She tended to suffer from constipation; stenoses at the cecum and colon cancer were detected by colon fiberscopy. Following surgical resection of the primary tumor, the patient received systemic chemotherapy with S-1, oxaliplatin, and bevacizumab. Following chemotherapy, CT showed no cancer in the lung and cancer reduction in the liver or dissemination. The patient had diarrhea and no appetite at first, so we reduced the oxaliplatin dose by 80%. After reduction of the oxaliplatin dose, we could treat the patient with S-1 and oxaliplatin continuously with no toxicity. S-1 and oxaliplatin chemotherapy is cost-effective, and has less toxicity than other chemotherapies, if proper measures are taken. It seemed to have a non-inferior response rate and disease control compared to other chemotherapies, such as FOLFOX. Thus, this chemotherapy is a valid choice for metastatic colorectal cancer.
要旨
進行・再発大腸癌に対して新たにSOX療法,またbevacizumab(BV)を併用したSOX+BV療法が使用されるようになった。今回,当院で初めてSOX+BV療法を使用した症例を経験した。症例は69歳,女性。回盲部に狭窄を伴う全周性腫瘍,多発肝転移,肺転移,腹膜播種を認めた。結腸切除の後,SOX+BV療法を開始したところ肺転移はほぼ消失し,肝転移も縮小した。軽度の食欲不振,下痢を認めたが,投与量の調整で治療の長期的継続が可能であった。SOX,SOX+BV療法は適正な使用により患者にとって効果とともに認容性も高く,今後は進行・再発大腸癌における化学療法の選択肢の一つとして有用であると考える。
目次
Summary
Chemotherapy with S-1 and oxaliplatin is a new treatment for metastatic colorectal cancer. We present the first case of S-1, oxaliplatin, and bevacizumab therapy in our hospital. The patient was a 69-year-old woman with ascending colon cancer and multiple lung and liver metastases. She tended to suffer from constipation; stenoses at the cecum and colon cancer were detected by colon fiberscopy. Following surgical resection of the primary tumor, the patient received systemic chemotherapy with S-1, oxaliplatin, and bevacizumab. Following chemotherapy, CT showed no cancer in the lung and cancer reduction in the liver or dissemination. The patient had diarrhea and no appetite at first, so we reduced the oxaliplatin dose by 80%. After reduction of the oxaliplatin dose, we could treat the patient with S-1 and oxaliplatin continuously with no toxicity. S-1 and oxaliplatin chemotherapy is cost-effective, and has less toxicity than other chemotherapies, if proper measures are taken. It seemed to have a non-inferior response rate and disease control compared to other chemotherapies, such as FOLFOX. Thus, this chemotherapy is a valid choice for metastatic colorectal cancer.
要旨
進行・再発大腸癌に対して新たにSOX療法,またbevacizumab(BV)を併用したSOX+BV療法が使用されるようになった。今回,当院で初めてSOX+BV療法を使用した症例を経験した。症例は69歳,女性。回盲部に狭窄を伴う全周性腫瘍,多発肝転移,肺転移,腹膜播種を認めた。結腸切除の後,SOX+BV療法を開始したところ肺転移はほぼ消失し,肝転移も縮小した。軽度の食欲不振,下痢を認めたが,投与量の調整で治療の長期的継続が可能であった。SOX,SOX+BV療法は適正な使用により患者にとって効果とともに認容性も高く,今後は進行・再発大腸癌における化学療法の選択肢の一つとして有用であると考える。